| CXCL12 chemokine expression suppresses human pancreatic cancer growth and metastasis I Roy, NP Zimmerman, AC Mackinnon, S Tsai, DB Evans, MB Dwinell PloS one 9 (3), e90400, 2014 | 92 | 2014 |
| Structural basis for chemokine recognition by a G protein–coupled receptor and implications for receptor activation JJ Ziarek, AB Kleist, N London, B Raveh, N Montpas, J Bonneterre, ... Science signaling 10 (471), eaah5756, 2017 | 86 | 2017 |
| Chemokines and chemokine receptors: update on utility and challenges for the clinician I Roy, DB Evans, MB Dwinell Surgery 155 (6), 961-973, 2014 | 83 | 2014 |
| Pancreatic cancer cell migration and metastasis is regulated by chemokine-biased agonism and bioenergetic signaling I Roy, DM McAllister, E Gorse, K Dixon, CT Piper, NP Zimmerman, ... Cancer research 75 (17), 3529-3542, 2015 | 70 | 2015 |
| Cyclic AMP regulates the migration and invasion potential of human pancreatic cancer cells NP Zimmerman, I Roy, AD Hauser, JM Wilson, CL Williams, MB Dwinell Molecular carcinogenesis 54 (3), 203-215, 2015 | 70 | 2015 |
| Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma I Roy, KA Boyle, EP Vonderhaar, NP Zimmerman, E Gorse, ... Laboratory investigation 97 (3), 302-317, 2017 | 33 | 2017 |
| CXM: a new tool for mapping breast cancer risk in the tumor microenvironment MJ Flister, BT Endres, N Rudemiller, AB Sarkis, S Santarriaga, I Roy, ... Cancer research 74 (22), 6419-6429, 2014 | 28 | 2014 |
| Exploiting agonist biased signaling of chemokines to target cancer I Roy, AE Getschman, BF Volkman, MB Dwinell Molecular carcinogenesis 56 (3), 804-813, 2017 | 22 | 2017 |
| Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL J Zurko, I Nizamuddin, N Epperla, K David, JB Cohen, TK Moyo, T Ollila, ... Blood Advances 7 (12), 2657-2669, 2023 | 12 | 2023 |
| Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma I Roy, G Smilnak, M Burkart, E Hamilton, K Thorp, S Miyata, S Ma, B Pro, ... British Journal of Haematology 197 (1), 71-75, 2022 | 7 | 2022 |
| Chemokines in colitis: MicroRNA control I Roy, CT Veldkamp, BF Volkman, MB Dwinell Gut 63 (8), 1202-1204, 2014 | 7 | 2014 |
| Ultrasonographic comparison of the lateral epicondyle in wheelchair-user (and able-bodied) tennis players: A pilot study V Roy, L Lee, M Uihlein, I Roy, K Lee The journal of spinal cord medicine 44 (1), 29-36, 2021 | 6 | 2021 |
| Factors associated with unplanned transfers among cancer patients at a freestanding acute rehabilitation facility A Bhakta, I Roy, K Huang, J Spangenberg, P Jayabalan PM&R 14 (9), 1037-1043, 2022 | 3 | 2022 |
| A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer EE Rabin, M Kim, A Mozny, K Cardoza, AC Bell, L Zhai, P Bommi, ... Brain, Behavior, & Immunity-Health 21, 100449, 2022 | 3 | 2022 |
| Relationship Between Cachexia and the Functional Progress of Patients With Cancer in Inpatient Rehabilitation I Roy, K Huang, A Bhakta, E Marquez, J Spangenberg, P Jayabalan American Journal of Physical Medicine & Rehabilitation 102 (2), 99-104, 2023 | 2 | 2023 |
| Assessment of Cancer-Associated Cachexia—How to Approach Physical Function Evaluation J Fram, C Vail, I Roy Current oncology reports 24 (6), 751-761, 2022 | 2 | 2022 |
| Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy R Karmali, N Epperla, G Shouse, JT Romancik, TK Moyo, VP Kenkre, ... Blood 140 (Supplement 1), 10955-10957, 2022 | 1 | 2022 |
| Excellent local control with involved-field radiotherapy following CHOP chemotherapy: analysis of 145 patients with early-stage intermediate-grade non-Hodgkin’s lymphoma I Roy, J Yahalom International Journal of Radiation Oncology, Biology, Physics 51 (3), 362-363, 2001 | 1 | 2001 |
| Harnessing the Systemic Biology of Functional Decline and Cachexia to Inform more Holistic Therapies for Incurable Cancers A Willbanks, M Seals, R Karmali, I Roy Cancers 16 (2), 360, 2024 | | 2024 |
| A Phase Ib Study to Evaluate the Safety and Efficacy of Nivolumab in Combination with R-CHOP in High-Risk DLBCL O Odetola, S Ma, JN Winter, B Pro, I Roy, P Xie, B Zhang, G Koulogeorgas, ... Blood 142, 4462, 2023 | | 2023 |
